Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like Ted will come out with letter every quarter giving break down of what's there to come, thus ensuring bag holders don't lose HOPE
Bumka is not able to sell his Patented technology to Big pharma and Big Tobacco, just to only folks who have been holding bags
what bother's me is ONLY when it comes to Lexxy, all companies are taking their time, or rather doing Due Diligence and finding that Bunka's crap dehydratech delivery method is some farce to fool retail share holder's into Hoping some big Tobacco or big Pharma will partner with them for their technology.
Dehydratech delivery results and patents have been there and established for too long for any Big pharma to validate. Don't you think Bunka just rides on what's famous. You forgot Bunka annouced delivering Covid-19 vaccines and its studies using Dehydratech. Now he has announced GLP-1. Anything that's trending is what Bunka start's the "Animal" studies and gives HOPE to shareholders' like you that someday Big Pharma or Big Tobacco company will comes and this will go 50-100X from its value.
Altria gave more than 2 bil to Juul, but where not willing to give more than 1 mil (initial study) to Lexx. If you remember Biogen had started some studies with Lexxx on CBD delivery, and So did National Health Canada or some university. What were the outcomes.
I think bunka is all smoke and he is smart enough to know what's trending. Seems to be a Penny stock company that has managed to fool its shareholders into resverse splitting and uplisting and giving HOPE that one day it will hit HOME Run
what bother's me is ONLY when it comes to Lexxy, all companies are taking their time, or rather doing Due Diligence and finding that Bunka's crap dehydratech delivery method is some farce to fool retail share holder's into Hoping some big Tobacco or big Pharma will partner with them for their technology.
Dehydratech delivery results and patents have been there and established for too long for any Big pharma to validate. Don't you think Bunka just rides on what's famous. You forgot Bunka annouced delivering Covid-19 vaccines and its studies using Dehydratech. Now he has announced GLP-1. Anything that's trending is what Bunka start's the "Animal" studies and gives HOPE to shareholders' like you that someday Big Pharma or Big Tobacco company will comes and this will go 50-100X from its value.
Altria gave more than 2 bil to Juul, but where not willing to give more than 1 mil (initial study) to Lexx. If you remember Biogen had started some studies with Lexxx on CBD delivery, and So did National Health Canada or some university. What were the outcomes.
I think bunka is all smoke and he is smart enough to know what's trending. Seems to be a Penny stock company that has managed to fool its shareholders into resverse splitting and uplisting and giving HOPE that one day it will hit HOME Run
How come they didn't come looking for lexxy. If the technology were that great, one would expect big tobacco and big pharma in bidding war to enter in partnership for drug delivery platform
You might want to check the 13G/13D to see what % is institutional investor buying it. If Retail folks can be fooled into buying it, so can institutional investors. We don't know what kind of kick back or setting they have in place. I see it from the fact that if the technology was that good, by now , big tobacco, big pharma would have come knocking at their door.
U just keep on hoping. I don't think underlying technology is good enough otherwise Altria would have already bought 100% of lexaria nicotine
Also same applies to IND application
With just 6-7 employees this company is just creating hope and encashing it fill Bunka coffers
You answered it yourself. Why only unknown companies are getting partnered with Lexx , like BEER, or one for Cannabis gummies etc who he sold Lexx Cannabis subsidiary. What do big companies like Biogen/Altria know or understand about Dehydra-tech that we are not aware and is not so convincing for them to jump on it.
Looking at companies like TPST/ ALT/KALA, you feel this is going to go to $75 , the breakeven price for some who have been holding bags since $2.50 pre split, but it doesn't look like.
Analyst report place it from $2 to $10 at the most. One would think with such a small mcap and with so many revenue streams like Nicotine, GLP, Hypertension , Diabetes, Vitamins etc etc, i mean , this stock can be as high as $100-$200 , with licensing agreements of $50-100 mil in place by now.
I always thought that after human clinical trials of Nicotine, there will be some partner announcement who would invest/license and provide see capital for doing IND applicaions on Hypertension / Diabetes etc etc. But this guy is blowing only smoke and keeps on taking out some crap News wire report and keeps on diluting existing share holders.
The share count in 2 yrs have gone from 1.6 mil to 11 mil + including warrants., and we haven't even partnered with any big corporation in any of the revenue streams, Big tobacoo, Big Pharma, Big Vitamin , Big Health /Wellness
Ted Odashi is the only analyst who has access to Bunka and is equally involved in running #Bunka's own profitable empire for Bunka. No share holders are benefiting.
He did smartly repriced the Options, but the Warrant holders when it was $2-$3 are holding bags. The warrants were as low as .15 cents, and share price went from $7.50 to as low as .65 cents. I don't think #Bunka's action and vision are matching the facts.
The technology is only good for #bunka
There r ceos who are opportunist without having major reasons to make successful empire and bunka is one of them
When COVID drug came, he took out news abt testing and proving dehydra-technology is better than injected one
When GLP-1 came, he announced studies abt it
There r only 5 employees and all test r being done through sub contracts, how do u even know how much is being spent and pocketed as kick backs
None of his revenue streams have generated any revenue
The poviva tea , granola bar, gummies etc. Good he got rid of lexx cannabis
And we don't see any revenue from Beer or gummies co.
We have been hearing about partnerships and institutional investments since the time it got reverse split 30:1 , and it has been more than 2 yrs. The mcap has gone up 2.5x and share count 10x
If the technology were that good
And has been proven with human trials and not just rats, how come Altria which has already done investment in lexx nicotine subsidiary and has product on market inferior compared to lexx.dehydrtech delivery not jumping off their seats to partner or license it or buy out lexx nicotine for 100 mil when they did invest 2 billion in other co
If the technology is that great, by now Tobacco companies should be looking out for Lexx Nicotine. How come no deal even after human clinical trials.
That's the reason, it is hard to believe that human clinical trial of Hypertension would be any good to qualify for IND or it's approval. Cause by now, major Biotech firms would be jumping on their seat to partner with Lexx for its Hypertension/Diabetes or GLP-1 program.
Can u explain 650k volume and only.3% -ve, it has traded more than 5% of public float
ALT stock has doubled in 2 days, pharma co will grab small cap if they see something as promising. Look at TPST, even now it is 8x of the lows.
I think with Nicotine, hypertension and diabetes drug candidate, many top companies should be accumulating hand over fist, especially all institutions investors.
Since they r not doing it, I don't see Lexx will meet same.fate as TPST or other pharma with 30-50x from these . levels
Why didn't anyone ask him about human trials of Nicotine, why none of top Tobacco companies didn't venture into it even though he has clinically proven it has better absorbing rate than on the market products
The issue with Lexxy is , all the test are not getting converted into deals and that's the history and fact. So how r u so convinced this one will ?
None of the Tobacco companies or for that matter any other company has approached Lexxy after their human nicotine trial and that tells a lot about their studies.
Something just doesn't add up right, the IND application might not even qualify
https://www.linkedin.com/pulse/nicotine-pouches-market-analysis-key-players-updates/
Biggest problem is delivery
1> even after good results of nicotine human trials, no deals with any big tobacco company
2> no update on high blood pressure IND application
3> how do we trust if new studies on diabetic and weight loss drugs will yield any results based on above two issues.
Bunka will continue to burn cash without any results
Repeat of TPST. Went from.23 cents to $10 in 2 days with 13mil float.
I am expecting lexxy to touch $20
Tpst went from .23 to$10 with 13.5 mil OS on +ve news
Lexx is 9 mil OS , at $1, can hit $20 in one day
What's with nicotine news. We r better in human trials than existing products available in market, still no multi million deal for nicotine pouches?
It took more than 2yr and 5 month for the stock to go from $7/- to $2:50
and it took less than 2 weeks to go from $2:50 to 0.75
Looks like someone know that Nicotine data is f,,ked up and that explains why no interest from any of the Tobacco industry.
The only option is IND of Hypertension, which i now have doubts is any good
Bunka is running the biggest con of this century. He claims he is getting trails at fraction of the cost, but in reality he has managed to blow away $12 mil in 2 yrs.
There is absolutely no details on how much he is getting paid and all deals are mentioned without $ figure to it.
He is now raising $4 mil with 2 mil shares and 2 mil warrants.@0.95
I did vote on everything against Bunka and also no on repricing or giving away any free shares
say NO to 3, 4, and 5 questions, the new OS is 11+ mil shares and incentive shares will increase every year upto 10% of OS, so from current 550k to 1.1 mil, he is giving himself free shares - self enriching scheme and also repricing options.
He has conned again, had posted in shareholder letter that nicotine study results are due in 2nd qtr, the latest S1-A the dosing is not completing until 3rd qtr.
He mentioned he won't raise funds diluting current share holders, guess what, he is issuing 5.5 mil+ shares @2.26 as per S1/A and that too with a warrant
He has conned again, had posted in shareholder letter that nicotine study results are due in 2nd qtr, the latest S1-A the dosing is not completing only in 3rd qtr.
He mentioned he won't raise funds diluting current share holders, guess what, he is issuing 5.5 mil+ shares @2.26 as per S1/A and that too with a warrant
He is conman. How come Altria didn't pay more than initial 1 m , but paid in billions for pouch. The tobacco giants r not knocking on their door.
He fooled earlier with institutions ready to invest when uplisted and I don’t see any
I am disappointed with their results, their earlier guidance was $120-130 mil with all them combined, with this run rate and 5-10% qtr growth, they won't be more than than 90-95 mil with all the quarter's growth rate unless they are adding more stores.
The only way this goes up is that their x directors or x ceo's return back the shares they have been allotted and reduce the outstanding by 50-100 mil shares to accommodate the less revenue they will generated compared to the proforma revenues they had earlier suggested.
The paid a lot more in shares for companies that are not generating the revenue at which they got evaluated. They need to reduce the share count to reflect that by 50-100 mil shares,
Until the stock price goes over $30 and continues to stay there, Bunka and Docherty should reduce there Salaries. Pharma companies have a different valuations, but incase of LEXX with so many streams, why none of them are willing to loan even $5-10 mil. So if the technology/IP is so promising, by now one of these Pharma companies would shown some level of interest.
Forget Pharma, why has none of the bigger Alcohol, or Tobacco companies not shown any interest.
Salary's of startups like LEXX should not be more than $120-180k, especially knowing that he failed to bring Institutional invested that he touted prior to RS, he does not deserve such high salary, only when the share price goes back to $50 and stays there for more than 10 days is when he can claim $300k base salary.
They registered 1.6 mil warrants and it means they expecting the stock to go up substantially and expecting conversion of those @6.50, the min stock price for that has to be $9 to $12 for little bit profit. This is the last chance for someone to get in at bottom.
Comparing it with Aerna, I think this can go easy $500/-. ARNA OS is 61 mil and PPS 92 , mcap of 6.x bil, even in 1-2 yrs from now if we can keep float of 10 mil and get bought out by some such firm, we are looking for 500+
Pfizer buying Arena Pharma for 6.7b, why not LEXX?
Hard to explain that LEXX just has float of 6 mil shares as OS and may be 4.5-5 public float, rest is with Bunka, then how come the shares trade 12-13 mil on news and shares only go 40-60% from 4.5 to 7.0
and when it trades like 50 mil ,it hardly goes 120-180% up
It's hard to explain with a low floater that it is not going 5x or 10x on big new's.
If UNRV and HBORF merge, that will double the revenue as both operate in CA & OR and are in similar range of $130 mil projections for 2022. That will benefit both
Based on what I see with ORMP, this will fly to $2.50 pre split as soon as some BigPharma joins hands. Am expecting sometime early next year.
Check out ORMP, similar to LEXX, already up 10X in 1 yr.
I think a big news on the way, merging with some company in CA for taking 2022 revenue guidelines to 200 mil +.
S-3 means , they might be working on a major merger for next year with some company and buying it now is the right time. Next year those companies can become more costlier.
SNDL or one of the Canadian LP listed in Nasdaq might go for similar deal as TLRY
Sndl csn buy stske in ianthus
I think Bunka take $300k salary and keep's on buying his own stock with all the free money he get's for doing nothing. As soon as he step's down, this stock will go up. He has been blowing smoke all along. If the technology were that good Altria would have invested more than 1 mil in it. Even after all these trial's , not a single big name has come forward.
That tell's a lot that Dehydratech is not the best delivery method there is
SNDL has so much cash, it can strike similar deal with iAnthus. Pay of their debt and take stake in iAnthus just like TLRY